Balerion Advisor Doug McAdams sits down with Mari Anne Snow, CEO of Eascra Biotech, to discuss Janus-based nanomaterials (JBNs) as a novel form of drug delivery, and in-space biomanufacturing. Eascra is developing Janus-based nanoparticles for targeted therapeutic delivery, with early applications in osteoarthritis, kidney disease, and solid tumors. The conversation examines how the platform works, why microgravity improves particle formation, and how the company is building both Earth-based and in-space manufacturing pathways.
Timestamped Overview
00:00 – Introduction to Eascra Biotech and Mari Anne Snow’s path to co-founding the company with UConn professor Yupeng Chen02:23 – Chen’s scientific background and the origins of the Janus-based monomer platform inspired by DNA05:03 – How the Janus-based nanoparticle works, including targeting, tissue penetration, endosomal delivery, and immune profile09:37 – The broader drug-delivery landscape and why customizable delivery systems remain a bottleneck in personalized medicine14:19 – Delivery routes, toxicity reduction, and how the platform may improve existing therapeutics by targeting them more precisely18:19 – Eascra’s lead osteoarthritis program, its strategy to advance toward clinical trials, and the role of pharma partnerships21:51 – How the nanoparticles are manufactured, from monomer design and tube assembly to cargo loading and targeting optimization26:01 – Why Eascra began working in microgravity, NASA’s in-space manufacturing support, and what the company learned from early ISS missions30:57 – How microgravity improves particle uniformity, loading, and efficacy, and why Eascra views the space-made product as a 2.0 version32:22 – Partnerships across NASA, CASIS, AFWERX, NSF, pharma, and emerging commercial space infrastructure providers36:21 – Current ISS operations, crew-enabled production, and the long-term goal of automated GMP-compliant in-space manufacturing40:02 – Regulatory strategy, including early engagement with the FDA and framing microgravity as a new manufacturing environment rather than a new standard43:05 – Particle stability, mRNA protection, and the potential to reduce or eliminate cold-chain requirements for certain therapeutics44:23 – Eascra’s long-term roadmap: bringing an Earth-based product to market while developing a supply chain and pathway for space-manufactured therapeutics49:35 – Why building a preclinical biotech company is hard, why space is only one additional challenge, and Snow’s closing reflections on collaboration across the sector
